« Return to News | R&D Trends

China-based WuXi Reports Successful Second Quarter

Tuesday, August 19, 2008 11:18 AM

A year after going public on the New York Stock Exchange, Chinese contract research, development and manufacturing company WuXi PharmaTech reported second quarter net revenues of $70.8 million—a 134% increase compared with the same period last year.

Established in 2000, WuXi has enjoyed several successes the past year. The company acquired a U.S.-based laboratory services supplier in January, and in late June, WuXi and contract research organization (CRO) Covance announced plans to form a partnership to provide preclinical contract research services in China, a move that will enable WuXi to access Covance’s deep customer base. WuXi's current big pharma clients include Merck and AstraZeneca. In addition to its operations in China, WuXi runs R&D and manufacturing facilities in St. Paul, Minn.; Atlanta, Ga; and Philadelphia, Pa.

According to WuXi’s second quarter earnings report, net revenues from laboratory services increased to $45.2 million, up 80% from Q2 2007, and manufacturing services net revenues grew almost 400% to $25.6 million. The January acquisition of AppTec was supposed to have contributed to WuXi’s impressive revenue growth, but WuXi did not provide specific financial details about this acquisition.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.